This retrospective, single-center study evaluated 101 T2DM patients prescribed the Dapagliflozin –Vildagliptin FDC over a three-month period. Of these, 49 patients completed the follow-up and were included in the final analysis. Patients were on existing antidiabetic therapy, with the FDC added as an add-on treatment. Key findings of the study are:1.Glycemic Control: Mean HbA1c decreased from 8.87% at baseline to 7.22%, a reduction of 1.65%. Dapagliflozin 5 mg + Vildagliptin 50 mg FDC offers a safe and effective option for improving glycemic and metabolic outcomes in T2DM Patients with CV Risk Factors.